GLPwatch
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
J Diabetes · 2013
Last updated 2026-05-28This review covers two newer classes of diabetes drugs introduced in the past 8 years: GLP-1 receptor agonists and DPP-4 inhibitors. Both work by targeting the 'incretin defect' in people with type 2 diabetes, which affects how the body regulates blood sugar.
AI summary of the abstract below.
| Journal | J Diabetes, 2013 |
|---|---|
| Citations | 7 |
| Relative citation ratio | 0.24 |
| NIH percentile | 15 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon-like peptide-1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called "incretin defect" in patients with T2DM.
Verbatim abstract via PubMed 23489968 ↗